Valvular & structural heart disease
Impact of dual atrioventricular valve disease on outcomes in patients undergoing transcatheter aortic valve replacement
Authors' conclusion
These findings underscore the importance of recognizing DAVR as a high-risk condition in TAVR patients, highlighting the need for refined risk stratification tools and potential adjunctive therapeutic strategies to improve outcomes.
Study context
- Population
- Patients who underwent transcatheter aortic valve replacement (TAVR) between 2013 and 2021consecutive patients who underwent TAVR
- Participants
- 3,491 patients
- Exposure
- Dual atrioventricular valve regurgitation (DAVR) vs isolated mitral regurgitation (MR), isolated tricuspid regurgitation (TR) and no/mild atrioventricular (AV) regurgitation
- DAVRn = 269
- Outcome
- Survival
- Follow-up
- 3 years
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
3-year mortality (multivariate analysis)
- DAVR as independent predictor, HR
- 1.36, 95% CI 1.1-1.8, P = 0.021
- Comparator not stated
Survival in DAVR patients with leading TR ≥ 3+ · 3 years
- 3-year survival, DAVR with leading TR ≥ 3+
- 27%
Survival by MR improvement following TAVR
- MR improvement, HR
- 0.45, 95% CI 0.30-0.69, P < 0.001
- Linked to better survival
Survival by TR improvement following TAVR
- TR improvement, HR
- 0.69, 95% CI 0.45-1.05, P = 0.086
- No significant impact on survival
Significant exertional dyspnoea (NYHA ≥ II) in DAVR patients · follow-up
- DAVR patients with NYHA ≥ II
- 54%
Original publication
Impact of dual atrioventricular valve disease on outcomes in patients undergoing transcatheter aortic valve replacement. Eur Heart J Cardiovasc Imaging. Published 11 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →